The Series D round values the payments infrastructure provider at $1.4bn and includes participation from several existing investors.
"The opportunity in software is enormous, with tens of thousands of incredibly innovative businesses bringing great products to market every year. Unfortunately, many SaaS companies still find their growth hindered by the operational challenges that arise when scaling; from handling subscriptions management or tax compliance to localizing payment options in every market. Paddle was created to remove these invisible barriers so that SaaS companies can just focus on building and selling software. 2021 was a fantastic year for us, but we are only just getting started. We have big plans for 2022 and beyond and we’re delighted to have the backing of so many fantastic investors who all share our vision."
The Series A round was led by Atomico with participation from notable angel investors and existing backers.
"This is the first time we have seen a tool really designed with the needs of business owners in mind, empowering them with access to everything they need in one place, in a world where most teams are still forced to buy multiple fragmented solutions, work in silos, or pay high legal fees to outside experts"
Element Ventures led the Series A round with participation from Fuel Ventures and Silicon Valley Bank.
"The traditional model for knowledge sharing lacks innovation and is cost prohibitive to scale. At Arbolus we’re building a platform that breaks that framework and gives professionals more autonomy. We are driven by the mission of making the world’s offline knowledge digitally accessible to a much wider customer base. We want to index the world’s human knowledge and make that widely searchable for the first time"
The syndicate included Mark Bamforth, Tern Plc, SIS Ventures, and Scottish Enterprise.
"2022 promises to be a big year for Talking Medicines with this new investment. Having scaled up our operations and formally launched our PatientMetrx® technology platform, we’ve now got our sights set on expanding in the US pharma market, providing brand teams and agencies with a new way of understanding what patients are really saying and feeling about their medicines. The pharmaceutical industry will go through seismic change this year and our actionable patient insights will be transformational for the industry. Our new office in New Jersey provides the ideal base for us to build relationships with customers, acquire new leads and drive revenue growth."
